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1Stroke risk and poststroke disability have steadily decreased in the United States over the past 2 decades because of 
improved prevention and access to reperfusion therapies for 
acute ischemic stroke, such as tPA (tissue-type plasminogen 
activator; alteplase) and endovascular thrombectomy. Despite 
the efficacy and safety of thrombolysis and thrombectomy, not 
all patients who receive the treatment improve to full, indepen-
dent recovery, and most patients are ineligible for treatment. 
Additionally, there are no efficacious treatments to improve 
long-term outcomes for patients after the acute phase of isch-
emic stroke or to reduce brain injury induced by acute intrace-
rebral hemorrhage. Therefore, development of new therapies 
for both acute and chronic stroke is sorely needed.
Stroke occurs because of a variety of vascular pathologies 
and injury mechanisms, some of which are difficult to model in 
animals. With the exception of reperfusion therapy, preclinical 
research end points do not generally reflect clinical outcomes. 
Pharmacodynamics, pharmacokinetics, and target engagement 
in the human brain need to be further developed and optimized 
for stroke interventions so that drug level in brain tissue, time 
to initiation, and duration of treatment can be accurately mea-
sured in clinical trials. Many variables, such as heterogeneity 
of vascular pathologies, patient demographics, and a host of 
comorbid conditions, as well as the lack of validated biomark-
ers to stratify patient populations, limit the ability of typical 
stroke clinical trials to detect a treatment effect.
To address these gaps, the National Institute of Neurological 
Disorders and Stroke organized and sponsored the workshop 
Translational Stroke Research: Vision and Opportunities, 
which was held in Bethesda, Maryland, on November 1 to 2, 
2016. The workshop gathered over 180 registered participants 
from academia, industry, the Food and Drug Administration, 
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and other public and private funding agencies. In the context 
of this workshop, translation refers to the research necessary 
to move a promising therapeutic along the drug development 
pipeline. Preclinical translational studies need to be designed 
differently depending on whether they are exploratory or 
confirmatory. Exploratory approaches may focus on disease 
mechanisms and use simpler rodent models to gain rigorous 
information on a putative therapeutic target. However, later-
stage confirmatory studies of putative therapies would benefit 
from the same design features adopted in clinical trials, includ-
ing heterogeneous populations, adequate sample size, end 
points predictive of clinical outcomes, and routes of admin-
istration similar to therapeutic use, as well as reporting of 
study results, including negative findings. This special report 
outlines the discussions and recommendations developed by 
the workshop participants to help advance translational stroke 
research, which are summarized in the Table.
Animal Models
The development and selection of the appropriate animal 
models depend on whether the study aims to address mecha-
nism or target of interest, to document preclinical efficacy, or 
to establish safety/toxicology evidence to support human tri-
als. A class of agents with a defined biological target and dem-
onstrated safety in humans may require only directed limited 
preclinical research for support, whereas unproven treatment 
modalities may require a more rigorous and extensive pre-
clinical evidence before proceeding to expensive human trials.
The entire spatiotemporal evolution of stroke pathology needs 
to be better understood, both early after the ischemic event, 
Table.  Scientific Priorities From the NINDS-Sponsored Workshop Translational Stroke Research: Vision and Opportunities
 Recommendations
 1–3 years
Preclinical outcome measures Development of preclinical outcome measures that align with phase II human outcome measures, including cognitive and 
other outcome measures, with a reasonable therapeutic window. Different approaches and outcomes may be needed based 
on the type of study (discovery vs confirmatory). Identify reliable biomarkers.
Experimental animal models Improve the understanding of how experimental animal models are similar or different in recapitulating human stroke. More 
research is needed to validate preclinical targets to make sure they are applicable for the human population. Moreover, many 
features associated with human stroke are not adequately recapitulated in experimental studies. Adequate animal models 
for age, comorbid human conditions, atrial fibrillation, hypoperfusion, transient ischemic attacks, white matter damage, or 
chronic stroke with persistent deficits need additional development and emphasis. End points should depend on the particular 
question being addressed. It may be valuable to use different models and different outcomes.
Preclinical standards and 
common data elements
Develop best preclinical practices guidance, small animal imaging guidelines, and preclinical CDEs for stroke, for clinical, 
radiological, molecular, and other forms of measurement. Preclinical stroke researchers should agree on a set of common 
data elements for reporting of their results. Minimum quality criteria (standards) should be established for exploratory 
(discovery) and confirmatory studies (prevention of bias, statistics, etc).
Collaboration between preclinical 
and clinical scientists
Incentivize Team Science between clinical and preclinical investigators via T32 funding for trainees, or a Clinical and 
Translational Science Awards–based mechanism, or through hands-on approach specialized training courses.
Multicenter network approach 
for late preclinical testing of 
promising therapies
Preclinical multilaboratory trials of a putative treatment may be valuable before investing in a clinical trial. Such multicentered 
preclinical testing is complex and should include, at a minimum, an agreed upon protocol that all laboratories would follow; 
rigorous good laboratory practices; a centralized randomization and data center; on-site source verification of data; and early 
validation of targets in humans. Such approaches should only be considered for a highly promising therapy that is under 
consideration for late-phase human trials. Incentives and requirements for participation should be discussed.
Independent replication Preclinical results should be independently replicated before moving into clinical testing. Specifics of such a requirement need 
to be worked out (definition of successful replication, strength of evidence, degree of interlaboratory standardization, multisite, 
academia vs Contract Research Organization, etc).
Publish/report negative data Publication or public use data set of negative findings is critical for moving translational stroke research forward. This could 
be a requirement for all NIH-funded preclinical stroke research.
 4–5 years
Clinical outcome measures Develop new and better outcome measures for phase II and phase III clinical trials. Clinical trials traditional end points 
are widely used and well validated. However, new predictive and standardized end points that also incorporate cognitive 
outcomes and recovery of function are needed. A workshop specifically targeting end points, such as the workshop held 
during the NINDS tPA for acute stroke trial that resulted in the global outcomes measure, is desirable.
Stroke repositories and biobanks Create data repositories and include stroke in biobanks.
Interaction with vascular 
contributions to dementia and 
other fields
Facilitate interaction and collaboration with the field of small vessel disease/vascular dementia/cerebral amyloid angiopathy 
and vascular contributions to cognitive impairment and dementia. Consider systemic effects, not just the brain (eg, cardiology, 
immunology).
Standardization and monitoring 
of preclinical studies
Confidence in results from preclinical studies must be underpinned by verification. Specifics of such monitoring/auditing need 
to be defined (random inspection, peer vs institutional, responsibility of funders and journals, funding, etc).
CDE indicates common data elements; NIH, National Institutes of Health; NINDS, National Institute of Neurological Disorders and Stroke; and tPA, tissue-type 
plasminogen activator
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when reperfusion and neuroprotection are key targets, as well 
as days–weeks–months poststroke, when repair and regenera-
tion are critical. Many preclinical studies focus on lesion volume 
as the primary outcome, as well as behavior outcomes at early 
time points postinfarct. Unlike stroke patients, however, rodents 
often show full spontaneous recovery of function, particularly 
when crude behavioral tests are used. There is a need to further 
develop animal models with persisting deficits that mimic the 
human condition. In addition, outcome measures that include 
the poststroke recovery stage are needed to better characterize 
long term brain adaptation and plasticity. Without examining 
sensitive outcome measures at later time points (30–90 days or 
longer) in preclinical models, translational potential may be lim-
ited. Since rodents may exhibit masking of functional deficits 
and a parallel compensation of sensor and motor disability, more 
sensitive and specialized tests to help discriminate recovery from 
compensation are needed. There is also a need to recapitulate the 
impact and heterogeneity of cortical, subcortical, and combined 
ischemic injury in animal models. To better translate optimal 
dosing from animals to humans, confirmatory preclinical studies 
should provide full dose–response curves, pharmacokinetic and 
pharmacodynamic modeling, and measurements of drug con-
centrations within the blood and cerebrospinal fluid. The Food 
and Drug Administration–published guidelines on dose transla-
tion are applicable to multiple disease states and are based on 
body surface area rather than body weight.1
The panel discussed whether data from large animal models 
are needed to justify moving into human trials. Although small 
and large animal models may be similar at the cellular level, 
they differ at the system level and in their immune responses. 
Furthermore, the organization of descending pathways differs 
between rodents and primates, and the repertoire of behavioral 
tests available for nonhuman primate studies is more extensive 
than those used in rodents. Nonhuman primates also offer the 
opportunity to generate informative data about important facets 
of human stroke pathophysiology, such as collateral flow, gyr-
encephalic white matter injury, adaptive recovery and return 
of physical function, cognitive testing, scaling studies of lepto-
meningeal arteries or astrocyte volume, and complex immune 
response. Understanding mechanisms in multiple rodent models 
prior to nonhuman primate research was considered important. 
Most importantly, a strong rationale, for instance, a target that 
cannot be modeled in rodents, is needed to ethically justify the 
use of nonhuman primates or other large animal species (eg, dog, 
sheep, pig models) with a statistically meaningful sample size.
An additional translational tool for predicting efficacy in 
humans, albeit less well documented, involves testing agents 
in vitro. With increased availability of human cell lines/tis-
sues, organoids, and inducible pluripotent stem cell tech-
nologies and high-throughput assays, in vitro strategies, in 
combination with data from animal models, may hold increas-
ing prominence in future drug development strategies.
Biological Variables: Age, Sex, and 
Comorbidities
The impact of age should be considered carefully in preclini-
cal studies because the mechanisms of stroke and response to 
drugs may be different in the developing, juvenile, adult, and 
geriatric brain. Similarly, sex can impact both the extent of 
stroke pathology and drug actions, and so evaluating agents in 
both sexes was considered critical. While using female rodents 
may seem to present challenges because of the estrous cycle, 
effective strategies to minimize these concerns are available. 
Using aged females after the cessation of the estrous cycle is 
a preferred approach to limit estrogen’s interference and to 
model perimenopause/menopause in women, typically associ-
ated with a higher risk of stroke. However, the demonstration 
of a beneficial effect in female animals, regardless of estrous 
stage, would also inform a potential therapy’s applications.
Preclinical studies are typically conducted in homogeneous 
groups for practical reasons, unlike patient populations typically 
enrolled in clinical trials. It is critical that investigators consider 
the variability in animal strain, stroke subtype and severity, collat-
eral status, time to and degree of reperfusion, immune status and 
response, and end points, to name a few, so that the preclinical 
premise is adequate to inform clinical trials. Animal models can 
also be designed to incorporate comorbidities, such as hyperten-
sion, obesity, diabetes mellitus, and hypercholesterolemia, which 
are highly prevalent in the targeted patient groups and may play 
important roles in stroke pathogenesis and outcome. Additionally, 
the possible interactions of potential stroke therapies being tested 
and drugs routinely used to treat relevant comorbidities should 
be further explored. Some, however, felt that using more basic, 
simple animal models would limit the confounders in the inter-
pretation of the results, particularly in early exploratory studies.
Preclinical and Clinical Outcome Measures
Preclinical outcome measures should recapitulate human clini-
cal features as nearly as possible, including infarct volume, 
neuroanatomical metrics, and behavioral/functional end points. 
However, the relationship between infarct volume and functional 
outcome has not been well validated in rodents or humans and 
complicates the transition to clinical trials. There are substantial 
measurement difficulties that remain a chronic problem of under-
recognition in both the preclinical and clinical worlds. Infarct 
volume assessment in preclinical studies using 2,3,5-triphenyltet-
razolium chloride may identify cells that are damaged but could 
eventually recover. Clinically, there is significant measurement 
uncertainty on exactly what magnetic resonance imaging or mul-
timodal computerized tomography modalities are measuring in 
humans. Studies should, thus, go beyond looking at only final 
infarct volume and instead more rigorously characterize ischemic 
injury in terms of changes in the core and penumbra over time. 
In preclinical studies, changes in cell numbers should be quanti-
fied using unbiased stereological approaches. New neuroimag-
ing modalities are available for use in both rodents and humans 
and should be further developed as complementary outcome 
measures in translational studies. Furthermore, the importance of 
lesion location in addition to infarct volume as a determinant of 
functional outcome should be underscored. Housing conditions, 
animal husbandry, and the presence or absence of an enriched 
environment should also be considered and reported because they 
might affect stroke outcome.
The selection of measures that lack good cross-species valid-
ity can derail translational efforts from the outset. Functionally 
relevant outcome measures that bridge across species, such 
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as edema formation, cerebral blood flow, and collateral sta-
tus, may provide translationally valuable data and need to be 
deployed more globally. In addition, some higher order behav-
ioral tasks for cognition and quality of life measures, such as 
depression, social isolation, and others, could interrogate neu-
robiological substrates common to rodents and humans.
Chronic Stroke and Stroke Recovery
Developing better animal models for chronic stroke and 
addressing mechanisms of stroke recovery were viewed as 
priorities. There are several animal behavioral and motor out-
come measures that assess distal extremity and fine motor 
control with relevance to human recovery.2–4 Sophisticated 
executive function tests in rodents capturing deficits seen in 
stroke patients were recently reported.5
Long-term consequences and natural history of stroke in 
humans need to be better characterized. There is also a disas-
sociation between quality of life measures from the patient 
perspective and neurological measures of recovery that needs 
further consideration. The modified Rankin Scale, consid-
ered as the gold standard for acute stroke reperfusion trials, 
presents limitations in its ability to capture smaller, but clini-
cally significant treatment effects on recovery after stroke and 
neurological deficits, such as aphasia, neglect, dexterity, and 
so on.6 A better tool to measure sensorimotor recovery after 
stroke is the Fugl–Meyer scale.7 Validation of more sensitive 
outcome measures for clinical trials should be a priority.
StrokeNet, Reverse Translation, 
and Team Science
The National Institute of Neurological Disorders and Stroke 
established the NIH StrokeNet (https://www.nihstrokenet.
org/) to maximize efficiencies in the development and con-
duct of NIH-funded multisite exploratory and confirmatory 
phase III clinical trials in stroke prevention, acute treatment, 
and recovery and to bridge the gap between basic clinical sci-
entists and clinicians.
The StrokeNet infrastructure and trial development help to 
address challenges for multisite trials, such as patient selec-
tion, effect size, study power, feasibility at sites, patient 
recruitment/retention, and selection of most relevant end 
points. StrokeNet could advance preclinical research by pro-
viding rigorously collected patient information to transla-
tional researchers, by incorporating biomarkers validated in 
preclinical studies, and by facilitating the dynamic interaction 
between clinical researchers, biostatisticians, and translational 
researchers to critically evaluate all facets of study design.
Generally, the stroke field lacks validated prognostic and 
diagnostic blood-based or neuroimaging biomarkers to strat-
ify patients or assess treatment outcomes. An available but 
underutilized resource for investigators at all phases of bio-
marker discovery research is the NIH NeuroBiobank (https://
neurobiobank.nih.gov). Well-described tissue or imaging 
brain banks with preclinical and clinical samples could accel-
erate early target validation.
Training of early career basic and clinical investiga-
tors could be enabled by a specific institutional training 
grant mechanisms, such as the NIH T32 or via the Clinical 
and Translational Science Awards–based training mecha-
nisms supported by the NIH National Center for Advancing 
Translational Sciences. Relevant examples are StrokeNet and 
the Canadian Partnership for Stroke Recovery course, Stroke 
Program in Neurorecovery (http://www.canadianstroke.ca/en/
training/events).
Lessons Learned From Previous Translational 
Efforts
Several tPA and endovascular trials for acute ischemic stroke 
indicate that when an intervention is beneficial, it shows effi-
cacy across several complementary outcome measures, with 
large effect sizes in patients who have salvageable brain tissue 
at the time of treatment. Key findings learned from reperfu-
sion trials include the axiom “time is brain,” reperfusion is 
generally helpful, the patient population is heterogeneous, 
spontaneous recanalization in the first 6 hours after ischemic 
stroke is uncommon, and it is difficult to predict prior to inter-
vention which patients are likely to respond. Furthermore, 
neuroprotective agents have been more effective in models of 
ischemia–reperfusion than in permanent ischemia. Most of the 
previous clinical trials for neuroprotection, however, enrolled 
patients in generally long-time windows (>4 hours); included 
only a minority of patients who underwent reperfusion; and 
enrolled a significant proportion of heterogeneous subjects 
who may or may not have salvageable brain tissue (ie, treat-
ment target was not directly verified).8,9 Results from animal 
models generally agree with these central tenets, but still there 
is a failure of translation. Is the problem, thus, with human 
trials or preclinical studies, or both? The answer to this ques-
tion would seem that there are deficiencies in both domains. 
Preclinical studies need to be more rigorously performed 
and embrace mechanisms to reduce both testing and report-
ing bias. Clinically, several recent human trials, eg, ACTION 
(natalizumab in acute neuroprotection)10 and AVERT (early 
mobilization in stroke),11 could have more carefully consid-
ered preclinical data. To challenge the assumption that ani-
mal studies need to model sex and comorbidities, the NA-1 
(Tat-NR2B9c) ENACT trial (Evaluating Neuroprotection in 
Aneurysm Coiling Therapy) was conducted in patients with 
iatrogenic stroke after endovascular aneurysm repair without 
previous testing in animals with comorbidities.12
Publication and Reporting of Negative Data
Publication bias represents a key gap in translational research. 
Publication of incomplete data sets and negative or null find-
ings at both the exploratory and confirmatory stage is critical 
to understand the entire research landscape. Yet for numerous 
reasons, negative findings are less likely to be published. Some 
avenues to disseminate negative data are becoming available 
through either traditional scientific journals or through the use 
of citable database descriptions. Thus, even if not published 
in article form, such data can be made publically available 
and could be used to generate more complete meta-analyses 
of prior research on potential therapies. A change in culture at 
universities and other institutions of higher learning to appre-
ciate the value of rigorously performed experiments that pro-
vide negative results should be promoted.
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New Approaches in Preclinical Stroke Research
A systematic review of the recent published literature on pre-
clinical stroke studies indicated that the quality of experimen-
tal design, as reflected in the use of randomization, blinding, 
and power calculation, was generally inadequately rigorous.13,14 
Because identical genetic backgrounds can develop differ-
ent phenotypes based on environment, different drug can-
didates should be tested in multiple laboratories and with 
different methods to ensure the robustness and reproducibility 
of the effect prior to investing in expensive clinical trials. In 
this regard, efforts from the Operation Brain Trauma Therapy 
consortium and the European Multicenter Preclinical Animal 
Research Team group demonstrated the feasibility of a multi-
laboratory approach embracing rigorous research principles.15,16
A multisite and interdisciplinary network for preclinical con-
firmatory studies could minimize bias, ensure quality control 
and adequate sample size, promote standardization across ani-
mal models, optimize and accelerate the selection of the most 
promising treatment candidate for clinical trials. If such a col-
laborative network can be developed, it could potentially lower 
the overall cost of preclinical testing by leveraging existing 
infrastructure. Issues such as incentives for the investigators, 
ensuring the expertise, training, and retention of highly quali-
fied personnel, protecting intellectual property, a rigorous selec-
tion process for candidate interventions, and increased upfront 
costs need to be carefully considered for this type of approach.
Replicating the phase I to III progression used in clinical 
trials, with progressively increased complexity and centralized 
oversight, could be a valuable approach in preclinical studies. 
Although intuitive, it remains uncertain if preclinical studies 
would be more predictive if conducted with the same standards 
as clinical trials. Another possible and parallel approach would 
be to design future clinical trials to more closely match the 
conditions of preclinical studies, by stratifying patient selec-
tion to include a more homogeneous stroke population in terms 
of subtype, mechanism, location, size, and severity of insult, 
matching end point selection, and excluding patients who are 
not likely to respond to treatment. For example, using neuro-
imaging to identify patients with salvageable penumbral tissue 
enabled successful completion of trials such as MR CLEAN 
(Multicenter Randomized Clinical Trial of Endovascular 
Treatment for Acute Ischemic Stroke in the Netherlands)17 and 
other endovascular trials. Selecting narrow patient populations 
would permit detection of small treatment effects but would 
also limit recruitment and generalizability of the results, poten-
tially reducing feasibility of a trial. This approach is consistent 
with the precision medicine initiative and could have advan-
tages in increasing efficiency and ultimately allow for targeting 
interventions to just those patients most likely to benefit.
Ensuring quality is a high priority for translational research. 
The value and feasibility of auditing/monitoring preclinical 
research, particularly in the confirmatory phase, to ensure 
data are gathered in a rigorous and standardized manner and 
could parallel the oversight that is used in clinical research. 
This topic and possible approaches for auditing (ie, journals, 
funding agencies, or reverse site visits between laboratories 
with similar expertise) were matters of debate and need to 
be further explored. Another approach, which can be done in 
concert with any auditing, would be to encourage or require 
reporting of all variables and bias controls such as excluded 
animals, method of randomization, postop care, and so on.
Harmonization and standardization of preclinical transla-
tional end points and the development of common data elements 
for data collection and reporting may help to reduce outcome 
variability and improve comparative analyses of the most infor-
mative measures. This approach has been embraced by clinical 
investigators and other preclinical fields,18–24 and its value for 
stroke translational research should not be underestimated.
Conclusions
Preclinical research continues to play an essential role to 
increase the confidence to further invest in potential new 
therapeutic candidates. Understanding the mechanisms of 
action across multiple experimental conditions is critically 
important. Success in neuroprotection could be enhanced 
by improving outcome measures, enabling more patients to 
access endovascular reperfusion and administering therapy by 
first responders. A robust signal of preclinical efficacy, with 
the highest quality standards, is necessary before moving an 
agent to a phase II/III clinical trial.
Ultimately, progress in promoting recovery and implement-
ing the potential new approaches and the cross-cutting priorities 
in preclinical and clinical research discussed at this workshop 
should facilitate future stroke therapeutic development.
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